Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide in Autistic Children With a Known Etiology
NCT02947880Phase 2Withdrawn
- Sponsor
- CHU de Limoges
- Start
- Dec 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Bumetanide group with Placebo group (2 arms). Primary endpoint: Childhood Autism Rating Scale at Day 99. Planned start Dec 2016; status: withdrawn.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02947880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947880.